Article Sidebar

PDF
Date Published: 17/02/2023
Abstract Views: 1113
Views PDF: 1936
DOI: https://doi.org/10.51298/vmj.v520i2.4155
Issue
Vol. 520 No. 2 (2022)
Section
Các bài báo
How to Cite
Đặng, X. V. ., Khiêu, H. T., & Nguyễn, T. T. U. (2023). OVERVIEW OF THE INTRATYMPANIC STEROID TREATMENT IN MÉNIÈRE DISEASE. Vietnam Medical Journal, 520(2). https://doi.org/10.51298/vmj.v520i2.4155

OVERVIEW OF THE INTRATYMPANIC STEROID TREATMENT IN MÉNIÈRE DISEASE

Xuân Vinh Đặng1,2,, Hữu Thanh Khiêu2, Thị Tố Uyên Nguyễn1
1 Hanoi medical university
2 ThaiBinh University of Medicine and Pharmacy

Main Article Content

Abstract

Objectives: Overview intratympanic Steroid treatment in Ménière's disease. Study design: Scoping review. Methods: Using databases from Pubmed website, Hanoi Medical University Library and manual search (January 2016 to December 2021). Result: we found 405 articles in the search terms, which adds up to 14 articles that met the selection criteria. Fourteen articles were published on 830 patients with two different extra-tympanic tympanic medications, including Intratympanic Dexamethasone (ITD), Intratympanic Methylprednisolone (ITM), and were included in the analysis. We conducted an analysis of the injection method, dosing and treatment effectiveness of the two drugs listed above. Conclusion: Intratympanic Steroid injections are effective in the short-term control of vertigo with deterioration in vertigo control over time. The protective ability to restore hearing with Intratympanic steroid injections is unclear.

Article Details

Keywords

Ménière Disease (MD), Intratympanic Dexamethasone (ITD), Intratympanic Methylprednisolone (ITM).

References

1. Basura GJ, Adams ME, Monfared A, et al. Clinical Practice Guideline: Ménière’s Disease. OtolaryngolHead Neck Surg. 2020;162 (2_suppl): S1-S55.doi:10.1177/0194599820909438
2. Molnár A, Maihoub S, Tamás L, Szirmai Á. Intratympanically administered steroid for progressive sensorineural hearing loss in Ménière’s disease. Acta Oto-Laryngologica. 2019;139 (11):982-986. doi:10.1080/ 00016489.2019.1658898
3. Weckel A, Marx M, Esteve-Fraysse MJ. Control of vertigo in Ménière’s disease by intratympanic Dexamethasone. European Annals of Otorhinolaryngology, Head and Neck Diseases. 2018;135(1):7-10. doi:10.1016/ j.anorl.2017.07.002
4. shamas I ul. Short Term Results of Intra Tympanic Gentamicin and Dexamethasone on Hearing and Tinnitus in Ménière’s disease: A Case Control Study. The International Tinnitus Journal. 2017;21(1). doi:10.5935/0946-5448.20170005
5. Masoumi E, Dabiri S, Ashtiani MTK, et al. Methylprednisolone versus Dexamethasone for Control of Vertigo in Patients with Definite Ménière’s disease. :6.
6. Beyea JA, Instrum RS, Agrawal SK, Parnes LS. Intratympanic Dexamethasone in the Treatment of Ménière’s Disease: A Comparison of Two Techniques. Otology & Neurotology. 2017;38 (6):e173-e178. doi:10.1097/MAO.0000000000001437
7. Naples JG, Henry L, Brant JA, Eliades SJ, Ruckenstein MJ. Intratympanic Therapies in Ménière Disease: Evaluation of Outcomes and Early Vertigo Control: Intratympanic Therapy in Ménière Disease. The Laryngoscope. 2019;129(1):216-221. doi:10.1002/lary.27392
8. Al Attrache NA, Krstulovic C, Pérez Guillen V, Morera Pérez C, Pérez Garrigues H. Response Over Time of Vertigo Spells to Intratympanic Dexamethasone Treatment in Ménière’s Disease Patients. Int Adv Otol. 2016;12(1):92-97. doi:10.5152/iao.2016.2177